RPG Life Sciences Limited
RPG Life Sciences Limited (RPGLIFE) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
rpglifesciences.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-02
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Sales | 143 Cr | 169 Cr | 182 Cr | 180 Cr | 177 Cr | 196 Cr |
| Operating expenses (approx.) | 118 Cr | 133 Cr | 143 Cr | 140 Cr | 144 Cr | 152 Cr |
| EBITDA | 25 Cr | 35 Cr | 39 Cr | 40 Cr | 33 Cr | 43 Cr |
| OPM % | 17.8% | 21.0% | 21.5% | 22.1% | 18.6% | 22.1% |
| Other income | 5 Cr | 5 Cr | 5 Cr | 3 Cr | 12 Cr | 5 Cr |
| Interest | 0.18 Cr | 0.13 Cr | 0.12 Cr | 0.25 Cr | 0.39 Cr | 0.63 Cr |
| Depreciation | 5 Cr | 5 Cr | 5 Cr | 5 Cr | 6 Cr | 6 Cr |
| Profit before tax | 135 Cr | 35 Cr | 49 Cr | 29 Cr | 40 Cr | 41 Cr |
| Tax % | 13.0% | 25.8% | 25.5% | 24.0% | 25.6% | 25.8% |
| Net profit | 117 Cr | 26 Cr | 37 Cr | 22 Cr | 30 Cr | 31 Cr |
| EPS (₹) | ₹70.96 | ₹15.90 | ₹22.28 | ₹13.38 | ₹18.08 | ₹18.60 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|
| Sales | 653 Cr | 708 Cr | Sign in for TTM |
| Operating expenses (approx.) | 494 Cr | 560 Cr | Sign in for TTM |
| EBITDA | 160 Cr | 147 Cr | Sign in for TTM |
| OPM % | 24.4% | 20.8% | Sign in for TTM |
| Other income | 13 Cr | 26 Cr | Sign in for TTM |
| Interest | 0.62 Cr | 0.89 Cr | Sign in for TTM |
| Depreciation | 21 Cr | 21 Cr | Sign in for TTM |
| Profit before tax | 233 Cr | 154 Cr | Sign in for TTM |
| Tax % | 21.3% | 25.3% | Sign in for TTM |
| Net profit | 183 Cr | 115 Cr | Sign in for TTM |
| EPS (₹) | ₹110.80 | ₹18.08 | Sign in for TTM |
| Dividend payout % | 14.4% | 34.5% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Equity capital | 13 Cr | 13 Cr |
| Reserves | 517 Cr | 592 Cr |
| Borrowings | — | 20 Cr |
| Other liabilities | 127 Cr | 168 Cr |
| Total liabilities | 658 Cr | 793 Cr |
| Fixed assets (net) | 161 Cr | 192 Cr |
| CWIP | 4 Cr | 20 Cr |
| Investments | 127 Cr | 85 Cr |
| Loans & advances | 0 Cr | 9 Cr |
| Inventories | 93 Cr | 124 Cr |
| Trade receivables | 87 Cr | 117 Cr |
| Cash & bank | 29 Cr | 150 Cr |
| Other assets | 157 Cr | 96 Cr |
| Total assets | 658 Cr | 793 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Cash from operating activity | 78 Cr | 57 Cr |
| Cash from investing | -42 Cr | 86 Cr |
| Cash from financing | -27 Cr | -21 Cr |
| Net cash flow | 9 Cr | 122 Cr |
| Free cash flow (OCF − Capex) | 42 Cr | -9 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| ROCE % | 44.0% | 24.8% |
| ROE % | 34.5% | 19.0% |
| Debtor days | 48 | 60 |
| Inventory days | 307 | 332 |
| Days payable | 262 | 260 |
| Cash conversion cycle | 93 | 131 |
| Debt / equity | — | 0.03 |
| Current ratio | 3.90 | 3.52 |
| Net debt / EBITDA | -0.18 | -0.89 |
Compare with peers
Loading peers…